MNTA Momenta Pharmaceuticals Inc.

16.85
+0.26  (+2%)
Previous Close 16.59
Open 16.58
Price To Book 6.04
Market Cap 1,666,755,477
Shares 98,917,239
Volume 429,645
Short Ratio
Av. Daily Volume 534,799
Stock charts supplied by TradingView

NewsSee all news

  1. Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the

  2. Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  3. Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results

    CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  4. Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

    CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1 data due in 2020.
M230 (CSL730)
Healthy volunteers
Phase 2 data due 3Q 2020.
Nipocalimab (M281)
generalized myasthenia gravis (gMG)
Phase 2 data due 2021.
Nipocalimab (M281)
hemolytic disease of the fetus and newborn (HDFN)
Phase 1/2 initial data due 1H 2020.
M254
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data due 2021.
Nipocalimab (M281)
Warm Autoimmune Hemolytic Anemia (wAIHA)

Latest News

  1. Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the

  2. Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  3. Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results

    CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated

  4. Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

    CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated